Table III.

Significant SNPs associated with overall survival in stage II and III CRC patients receiving 5-FU-based adjuvant chemotherapy

SNP	Region (gene)	Alive/Dead	HRa (95% CI)	P value	Log-rank P
Stage III
rs961253b	20p12.3 (BMP2)
CC		55/15	1 (Reference)
CA + AA		89/11	0.24 (0.09–0.68)	0.007	0.054
rs355527b	20p12.3 (BMP2)
GG		63/15	1 (Reference)
GA + AA		80/11	0.29 (0.1–0.81)	0.019	0.179
rs4464148	18q21.1 (SMAD7)
AA + AG		133/21	1 (Reference)
GG		10/5	4.34 (1.46–12.89)	0.008	0.020
rs6983267b	8q24.21 (POU5F1P1, DQ515897, MYC)
CC		53/3	1 (Reference)
CA + AA		91/23	4.2 (1.13–15.64)	0.032	0.007
rs10505477b	8q24.21 (POU5F1P1, DQ515897, MYC)
AA		51/3	1 (Reference)
AG + GG		93/23	4.2 (1.13–15.64)	0.032	0.010

^aHR adjusted by age, gender, race, tumor location and histology grade.

^bLinkage SNPs.